Search results for "Cook"

showing 10 items of 660 documents

2021

This retrospective population-based study examined the impact of age and comorbidity burden on multimodal management and survival from colorectal cancer (CRC). From 2000 to 2015, 1479 consecutive patients, who underwent surgical resection for CRC, were reviewed for age-adjusted Charlson comorbidity index (ACCI) including 19 well-defined weighted comorbidities. The impact of ACCI on multimodal management and survival was compared between low (score 0–2), intermediate (score 3) and high ACCI (score ≥ 4) groups. Changes in treatment from 2000 to 2015 were seen next to a major increase of laparoscopic surgery, increased use of adjuvant chemotherapy and an intensified treatment of metastatic dis…

OncologyLaparoscopic surgerymedicine.medical_specialtyeducation.field_of_studyColorectal cancerbusiness.industrymedicine.medical_treatmentPopulationGeneral Medicinemedicine.diseaseComorbidity3. Good healthRadiation therapy03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisInternal medicinemedicineCarcinoma030211 gastroenterology & hepatologyStage (cooking)MetastasectomyeducationbusinessJournal of Clinical Medicine
researchProduct

Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non-muscle-invasive Urothelial Bladder Cancer

2018

Background: Serum levels of neutrophils, platelets, and lymphocytes have been recognized as factors related to poor prognosis for many solid tumors, including bladder cancer (BC). Objective: To evaluate the prognostic role of the combination of the neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and lymphocyte/monocyte ratio (LMR) in patients with high-risk non–muscle-invasive urothelial BC (NIMBC). Design, setting, and participants: A total of 1151 NMIBC patients who underwent first transurethral resection of the bladder tumor (TURBT) at 13 academic institutions between January 1, 2002 and December 31, 2012 were included in this analysis. The median follow-up was 48 mo.…

OncologyMaleBladder cancer; Lymphocyte/monocyte ratio; Neutrophil/lymphocyte ratio; Platelet/lymphocyte ratio; Prognosis; Aged; Biomarkers Tumor; Blood Platelets; Carcinoma Transitional Cell; Cystectomy; Disease Progression; Female; Follow-Up Studies; Humans; Inflammation; Lymphocyte Count; Lymphocytes; Male; Monocytes; Neutrophils; Prognosis; Risk Factors; Urinary Bladder NeoplasmsNeutrophilsmedicine.medical_treatmentLymphocyte:Medicina Básica [Ciências Médicas]Prognosis.030232 urology & nephrologyMonocyteMonocytesSettore MED/24 - Urologia0302 clinical medicineRisk FactorsLymphocytesStage (cooking)Framingham Risk ScoreTumorNeutrophilBladder cancerPrognosis3. Good healthmedicine.anatomical_structureOncology030220 oncology & carcinogenesisNeutrophil/lymphocyte ratioCiências Médicas::Medicina BásicaDisease ProgressionLymphocyteFemalemedicine.symptomHumanBlood Plateletsmedicine.medical_specialtyPlatelet/lymphocyte ratioPrognosiUrologyInflammationCystectomyFollow-Up StudieCystectomy03 medical and health sciencesInternal medicinemedicineBiomarkers TumorHumansRadiology Nuclear Medicine and imagingLymphocyte CountAgedInflammationCarcinoma Transitional CellBladder cancerScience & Technologybusiness.industryProportional hazards modelRisk FactorCarcinomaLymphocyte/monocyte ratioImmunotherapymedicine.diseaseUrinary Bladder NeoplasmsBlood PlateletSurgeryTransitional CellbusinessBiomarkersFollow-Up Studies
researchProduct

Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of …

2011

Purpose The purpose of this study was to develop accurate models and nomograms to predict local recurrence, distant metastases, and survival for patients with locally advanced rectal cancer treated with long-course chemoradiotherapy (CRT) followed by surgery and to allow for a selection of patients who may benefit most from postoperative adjuvant chemotherapy and close follow-up. Patients and Methods All data (N = 2,795) from five major European clinical trials for rectal cancer were pooled and used to perform an extensive survival analysis and to develop multivariate nomograms based on Cox regression. Data from one trial was used as an external validation set. The variables used in the ana…

OncologyMaleCancer ResearchColorectal cancerMESH : AgedKaplan-Meier EstimateMESH : Randomized Controlled Trials as Topiclaw.invention[ SDV.CAN ] Life Sciences [q-bio]/Cancer0302 clinical medicineRandomized controlled triallawMESH : FemaleStage (cooking)Neoplasm MetastasisMESH: Models TheoreticalMESH : Rectal NeoplasmsSettore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIARandomized Controlled Trials as TopicMESH: Aged0303 health sciencesMESH: Middle AgedMESH : Neoplasm Recurrence LocalAge FactorsMiddle AgedMESH : Adult3. Good healthEuropeOncology030220 oncology & carcinogenesisMESH : Neoplasm MetastasisFemaleMESH: Neoplasm Recurrence LocalAdultmedicine.medical_specialtyMESH : Sex FactorsMESH : MaleMESH : Europe[SDV.CAN]Life Sciences [q-bio]/CancerMESH : Kaplan-Meier Estimate03 medical and health sciencesRECTAL CANCERSex FactorsMESH: Sex FactorsInternal medicinemedicineHumansMESH : Middle AgedSurvival analysisMESH: Kaplan-Meier Estimate030304 developmental biologyAgedMESH: Age FactorsMESH: HumansProportional hazards modelbusiness.industryRectal NeoplasmsMESH : Models TheoreticalMESH : HumansMESH: Rectal NeoplasmsMESH: AdultNomogramModels Theoreticalmedicine.diseaseMESH: Neoplasm MetastasisMESH: MaleSurgeryClinical trialMESH: Randomized Controlled Trials as TopicMESH : Age FactorsMESH: EuropeNeoplasm Recurrence LocalbusinessMESH: FemaleChemoradiotherapy
researchProduct

Multi-state relative survival modelling of colorectal cancer progression and mortality.

2015

Abstract Accurate identification of factors associated with progression of colorectal cancer remains a challenge. In particular, it is unclear which statistical methods are most suitable to separate the effects of putative prognostic factors on cancer progression vs cancer-specific and other cause mortality. To address these challenges, we analyzed 10 year follow-up data for patients who underwent curative surgery for colorectal cancer in 1985–2000. Separate analyses were performed in two French cancer registries. Results of three multivariable models were compared: Cox model with recurrence as a time-dependent variable, and two multi-state models, which separated prognostic factor effects …

OncologyMaleCancer Researchmedicine.medical_specialtyEpidemiologyColorectal cancer01 natural sciencesCancer recurrence010104 statistics & probability03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineHumansRegistries0101 mathematicsStage (cooking)AgedNeoplasm StagingModels StatisticalMulti stateRelative survivalbusiness.industryProportional hazards modelCancermedicine.diseasePrognosis3. Good healthSurgerySurvival RateOncology030220 oncology & carcinogenesisCurative surgeryDisease ProgressionFemaleNeoplasm Recurrence LocalbusinessColorectal NeoplasmsCancer epidemiology
researchProduct

Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry.

2009

The Italian Neuroblastoma Registry was investigated to describe 781 children with neuroblastoma experiencing tumour recurrence (424 progressions and 357 relapses). Ten-year overall survival (OS) was 6.8% (95% confidence interval (CI) 4.3-10.0) after progression and 14.4% (95% CI 10.5-18.9) after relapse. For both circumstances, OS was better for age at diagnosis <18 months, less advanced International Neuroblastoma Staging System (INSS) stage, normal lactate dehydrogenase (LDH) serum level, normal MYCN gene status (P<0.001) and a non-abdominal primary site (P=0.034 for progression, and P=0.004 for relapses). A local type of recurrence had a significantly better outcome only in case of relap…

OncologyMaleCancer Researchmedicine.medical_specialtyPediatricsRisk factors MYCNNeuroblastomaSurvival relapse progressionRisk FactorsNeuroblastomaInternal medicinemedicineHumansStage (cooking)Risk factorChildSurvival analysisRetrospective StudiesSalvage Therapybusiness.industryCancerInfantRetrospective cohort studymedicine.diseaseSurvival AnalysisConfidence intervalOncologyItalyChild PreschoolCohortDisease ProgressionFemaleNeoplasm Recurrence LocalbusinessChildhood cancerEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Detection and characterization of tumor hypoxia using pO2 histography.

2007

Data from 125 studies describing the pretreatment oxygenation status as measured in the clinical setting using the computerized Eppendorf pO2 histography system have been compiled in this article. Tumor oxygenation is heterogeneous and severely compromised as compared to normal tissue. Hypoxia results from inadequate perfusion and diffusion within tumors and from a reduced O2 transport capacity in anemic patients. The development of tumor hypoxia is independent of a series of relevant tumor characteristics (e.g., clinical size, stage, histology, and grade) and various patient demographics. Overall median pO2 in cancers of the uterine cervix, head and neck, and breast is 10 mm Hg with the ov…

OncologyMalePathologymedicine.medical_specialtyTime FactorsPhysiologyClinical BiochemistryUterine Cervical NeoplasmsBreast NeoplasmsBiochemistryInternal medicineNeoplasmsMedicineHumansOximetryStage (cooking)Neoplasm MetastasisHypoxiaMolecular BiologyGeneral Environmental ScienceTumor hypoxiabusiness.industryHistologyCell BiologyOxygenationHypoxia (medical)Tumor OxygenationPrognosisOxygenHead and Neck NeoplasmsGeneral Earth and Planetary SciencesFemaleHemoglobinmedicine.symptombusinessPerfusionSoftwareAntioxidantsredox signaling
researchProduct

Comparative assessment of docetaxel for safety and efficacy between hormone-sensitive and castration-resistant metastatic prostate cancer.

2019

To compare toxicity and response of docetaxel chemotherapy between metastatic hormone-sensitive prostate cancer (mHSPC) and castration-resistant metastatic prostate cancer (mCRPC) patients of the same therapeutic era for assessing of upfront docetaxel against the benchmark of docetaxel in the castrate resistant stage in the setting outside of clinical trials.A prospectively collected database of real-world prostate cancer patients receiving docetaxel was divided in mHSPC and mCRPC cases and retrospectively analyzed. Principal objectives were toxicity measured by the common criteria of adverse events terminology and response characterized by Prostate specific antigen decline and radiographic…

OncologyMalemedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsUrologymedicine.medical_treatment030232 urology & nephrologyAntineoplastic AgentsDocetaxelSeverity of Illness Index03 medical and health sciencesProstate cancer0302 clinical medicineInternal medicinemedicineHumansProspective StudiesStage (cooking)Adverse effectAgedNeoplasm StagingRetrospective StudiesChemotherapyPerformance statusbusiness.industryProstateMiddle AgedProstate-Specific Antigenmedicine.diseasePrognosisProgression-Free SurvivalClinical trialRadiographyProstate-specific antigenProstatic Neoplasms Castration-ResistantOncologyDocetaxelClinical Trials Phase III as Topic030220 oncology & carcinogenesisDisease ProgressionKallikreinsbusinessmedicine.drugUrologic oncology
researchProduct

Prognostic Impact of pT Stage and Peritoneal Invasion in Locally Advanced Colon Cancer

2019

BACKGROUND: TNM stage has been identified as an independent variable for local recurrence and survival after colon cancer resection. It is still unclear whether peritoneal invasion (pT4a) is a risk factor for adverse oncologic outcome or whether these patients have better results compared with contiguous organs infiltration (pT4b), independent from nodal status (pN). OBJECTIVE: The purpose of this study was to analyze whether peritoneal invasion is an independent risk factor for worse oncologic outcome after curative colon cancer resection. DESIGN: This was a retrospective analysis with multivariate regression of a prospective database, according to Strengthening the Reporting of Observatio…

OncologyMalemedicine.medical_specialtySurvivalColorectal cancermedicine.medical_treatmentLocally advancedT stageLocally advanced colon cancer03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineColon cancer resectionHumansNeoplasm InvasivenessRisk factorStage (cooking)Survival rateColectomyPeritoneal NeoplasmsColectomyAgedNeoplasm StagingRetrospective StudiesCarcinomatosisTumor-node-metastasisbusiness.industryGastroenterologyRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseasePrognosisColon cancerSurvival RateTreatment Outcome030220 oncology & carcinogenesisColonic Neoplasms030211 gastroenterology & hepatologyFemaleNeoplasm Recurrence Localbusiness
researchProduct

Treatment of non-metastatic castration resistant prostate cancer in 2020: What is the best?

2020

Lately the development of 3 novel second-generation androgen receptor antagonists (enzalutamide, apalutamide, and darolutamide) chanced the treatment landscape of nonmetastatic castration-resistant prostate cancer. After proofing their clinical efficacy in large phase III registration trials with good compatibilities and tolerable side effects currently all 3 substances are Food and Drug Administration-approved in nonmetastatic castration-resistant prostate cancer. The present short review article provides an overview about these new treatment options and discusses their use in daily routine focusing on patient selection as well as on the impact of novel sensitive imaging modalities like pr…

OncologyMalemedicine.medical_specialtyUrology030232 urology & nephrologyHistory 21st Century03 medical and health scienceschemistry.chemical_compoundProstate cancer0302 clinical medicineInternal medicinemedicineEnzalutamideHumansAndrogen Receptor AntagonistsStage (cooking)Adverse effectAgedAged 80 and overbusiness.industryApalutamideMiddle Agedmedicine.diseaseReview articleProstatic Neoplasms Castration-ResistantDarolutamideOncologychemistry030220 oncology & carcinogenesisbusinessUrologic oncology
researchProduct

Is free/total PSA predictive of pathological stage and Gleason score in patients with prostate cancer and serum PSAor=10 ng/ml?

2005

&lt;i&gt;Introduction:&lt;/i&gt; To evaluate whether percent free prostate-specific antigen (%-fPSA) could be predictive of pathological stage and Gleason score in patients with prostate cancer (PCa) and serum PSA of 10 ng/ml or less. &lt;i&gt;Materials and Methods:&lt;/i&gt; In 100 patients with total PSA≤10 ng/ml who underwent radical retropubic prostatectomy as primary treatment of PCa, %-fPSA levels in organ-confined vs. non-organ-confined PCa and in patients with Gleason score ≤/&gt;7 were compared. &lt;i&gt;Results:&lt;/i&gt; 32 patients had an organ-confined and 68 a locally advanced PCa. Median %-fPSA level was 15%; Gleasonscore was &lt;7 in 49 patients, equal to 7 in 40 and &gt;7 i…

OncologyMalemedicine.medical_specialtybusiness.industryUrologyUrologyProstatic NeoplasmsMiddle AgedProstate-Specific Antigenurologic and male genital diseasesmedicine.diseaseProstate cancerAntigenInternal medicinemedicineHumansNeoplasm stagingIn patientProstate cancer stagingStage (cooking)businessPathologicalTotal psaAgedNeoplasm StagingUrologia internationalis
researchProduct